Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II/III clinical trial of its Category 1 biologic B013, combined with albumin paclitaxel, for first-line treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).
Drug Profile
B013, a potential first-in-class monoclonal antibody (mAb) under development to treat TNBC, was licensed from US-based Oncternal in September 2019, granting Shanghai Pharma exclusive rights in Greater China. The pre-clinical study in China concluded in December 2022.
Financials
Shanghai Pharma has invested RMB 43.69 million (USD 6.3 million) in B013’s development to date, according to a company press release.-Fineline Info & Tech
